One stock that might be an intriguing choice for investors right now is Intra-Cellular Therapies, Inc. ITCI. This is because this security in the Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Biomedical and Genetics space as it currently has a Zacks Industry Rank of 58 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.Meanwhile, Intra-Cellular Therapies is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.Intra-Cellular Therapies Inc. Price and Consensus Intra-Cellular Therapies Inc. price-consensus-chart | Intra-Cellular Therapies Inc. QuoteIn fact, over the past month, current quarter estimates have narrowed from a loss of $1.02 per share to a loss of 98 cents per share, while current year estimates have narrowed from a loss of $3.71 per share to a loss of $3.56 per share. This has helped ITCI to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.So, if you are looking for a decent pick in a strong industry, consider Intra-Cellular Therapies. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.The Hottest Tech Mega-Trend of All Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.See Zacks' 3 Best Stocks to Play This Trend >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intra-Cellular Therapies Inc. (ITCI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research